Study finds Moderna vaccine reduces symptomatic COVID-19 in young adults

A study conducted by a team of researchers including Rebecca Fischer, Ph.D., assistant professor in the Department of Epidemiology and Biostatistics at Texas A&M University School of Public Health, analyzed the efficacy of the Moderna mRNA-1273 vaccine in preventing infections and symptomatic COVID-19 in young adults. The study followed 1,149 young adults aged 18-29 over a six-month period and analyzed the vaccine’s impact on the incidence of SARS-CoV-2 infection and symptomatic COVID-19. The findings revealed that two doses of the vaccine had an efficacy of nearly 53 percent against infection and around 71 percent against symptomatic COVID-19 in young adults. The study was published in Open Forum Infectious Diseases.

Source link

error: Content is protected !!